SCHEMBL2923964

SCHEMBL2923964

Nc1cccc(Nc2c(-c3ccccc3)nc3cnccn23)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.69
GAA P10253 13/20 0.66
KDM4E B2RXH2 5/20 0.66
LMNA P02545 5/20 0.66
MAPK1 P28482 2/20 0.66
SYK P43405 1/20 0.60
MAPT P10636 9/20 0.57
TP53 P04637 2/20 0.57
ALDH1A1 P00352 7/20 0.56
HSD17B10 Q99714 3/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HPGD P15428 2/20 0.55
ALOX15 P16050 1/20 0.55
CASP1 P29466 1/20 0.55
CASP7 P55210 1/20 0.55
TUBB4A P04350 2/20 0.52
TUBB P07437 2/20 0.52
TUBA3C P0DPH7 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2923400 0.88 GAA (0.83) BRAFGAAKDM4ELMNAMAPK1
SCHEMBL2924128 0.87 GAA (0.78) BRAFGAAKDM4ELMNAMAPK1
SCHEMBL2943722 0.86 GAA (0.66) BRAFGAAKDM4ELMNAMAPK1
SCHEMBL2921992 0.86 GAA (0.77) BRAFGAAKDM4ELMNAMAPK1
SCHEMBL2919660 0.86 GAA (0.66) BRAFGAAKDM4ELMNAMAPK1
SCHEMBL2921758 0.86 BRAF (0.77) BRAFGAAKDM4ELMNAMAPK1
SCHEMBL2948843 0.83 GAA (0.78) BRAFGAAKDM4ELMNAMAPK1
SCHEMBL15452683 0.83 GAA (0.69) BRAFGAAKDM4ELMNAMAPK1
SCHEMBL2922900 0.83 BRAF (0.62) BRAFGAAKDM4ELMNAMAPK1
SCHEMBL31355339 0.83 SYK (0.85) BRAFGAAKDM4ELMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1901748-B1 ANGIOGENESIS INHIBITORS ONCALIS AG (CH) 2010-09-08 EP disclosed
EP-1901748-B1 ANGIOGENESIS INHIBITORS ONCALIS AG (CH) 2010-09-08 EP disclosed
EP-1765351-B9 PROTEIN KINASE INHIBITORS ONCALIS AG (CH) 2010-03-24 EP disclosed
EP-1765351-B1 PROTEIN KINASE INHIBITORS ONCALIS AG (CH) 2009-03-04 EP disclosed
US-20070149535-A1 Protein kinase inhibitors ONCALIS AG (CH) 2007-06-28 US disclosed
US-20070149535-A1 Protein kinase inhibitors ONCALIS AG (CH) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149535-A1 Protein kinase inhibitors FLT1, ERBB2, ERBB3 BRAF 42/4885GAA 3677/4885KDM4E 1064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.